| Dr Maria Elena Otayza-navato, MD | |
|
300 Se 2nd St Ste 201, Lees Summit, MO 64063-2759 | |
| (816) 404-6170 | |
| (816) 404-6210 |
| Full Name | Dr Maria Elena Otayza-navato |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Child & Adolescent Psychiatry |
| Location | 300 Se 2nd St Ste 201, Lees Summit, Missouri |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831278647 | NPI | - | NPPES |
| Entity Name | University Health Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669456257 PECOS PAC ID: 1153235825 Enrollment ID: O20031117000701 |
News Archive
Researchers have identified a drug that targets the first step in the toxic chain reaction leading to the death of brain cells, suggesting that treatments could be developed to protect against Alzheimer's disease, in a similar way to how statins are able to reduce the risk of developing heart disease.
Merck, known as MSD outside the United States and Canada, today announced that researchers will present new data analyses of the safety and efficacy of the company's investigational allergy immunotherapy tablets (AITs) for ragweed pollen (Ambrosia artemisiifolia) and grass pollen (Phleum pratense) at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.
TARIS Biomedical, a specialty pharmaceutical company pioneering the development of innovative, targeted therapies using drug delivery to treat bladder diseases with high unmet medical need, announced that it has initiated a Phase 1B clinical study in patients with interstitial cystitis (IC). The study will evaluate the safety and tolerability of TARIS' innovative product candidate LiRIS® in patients suffering from moderate-to-severe IC.
A common cancer drug and a drug used for a rare condition affecting the heart could together treat an aggressive form of lung cancer called non-small cell lung cancer (NSCLC), according to a study published in Cell today.
Amarantus BioScience, Inc., a biotechnology company discovering and developing treatments for diseases associated with protein misfolding and apoptosis, today announced that it has licensed the LymPro Alzheimer's Disease Diagnostic Blood Test (LymPro) from Memory Dx, LLC (MDx), formerly known as Provista Life Sciences, Inc.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Maria Elena Otayza-navato, MD 2310 Holmes St, Ste 800, Kansas City, MO 64108-2602 Ph: (816) 218-2523 | Dr Maria Elena Otayza-navato, MD 300 Se 2nd St Ste 201, Lees Summit, MO 64063-2759 Ph: (816) 404-6170 |
News Archive
Researchers have identified a drug that targets the first step in the toxic chain reaction leading to the death of brain cells, suggesting that treatments could be developed to protect against Alzheimer's disease, in a similar way to how statins are able to reduce the risk of developing heart disease.
Merck, known as MSD outside the United States and Canada, today announced that researchers will present new data analyses of the safety and efficacy of the company's investigational allergy immunotherapy tablets (AITs) for ragweed pollen (Ambrosia artemisiifolia) and grass pollen (Phleum pratense) at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.
TARIS Biomedical, a specialty pharmaceutical company pioneering the development of innovative, targeted therapies using drug delivery to treat bladder diseases with high unmet medical need, announced that it has initiated a Phase 1B clinical study in patients with interstitial cystitis (IC). The study will evaluate the safety and tolerability of TARIS' innovative product candidate LiRIS® in patients suffering from moderate-to-severe IC.
A common cancer drug and a drug used for a rare condition affecting the heart could together treat an aggressive form of lung cancer called non-small cell lung cancer (NSCLC), according to a study published in Cell today.
Amarantus BioScience, Inc., a biotechnology company discovering and developing treatments for diseases associated with protein misfolding and apoptosis, today announced that it has licensed the LymPro Alzheimer's Disease Diagnostic Blood Test (LymPro) from Memory Dx, LLC (MDx), formerly known as Provista Life Sciences, Inc.
› Verified 7 days ago
Dr. Roxane S Bremen, D.O. Psychiatry & Neurology Medicare: May Accept Medicare Assignments Practice Location: 622 Sw 3rd St, Ste B, Lees Summit, MO 64063 Phone: 816-398-7048 Fax: 913-562-9972 | |
Dr. Gary H Boxer, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 300 Se 2nd St Ste 100, Lees Summit, MO 64063 Phone: 816-404-6170 | |
Dr. David Edward Sternberg, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 527 Sw Market St, Lees Summit, MO 64063 Phone: 913-209-9495 Fax: 913-498-0523 | |
Dr. Karen Jean Haas, D.O. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2000 Se Blue Pkwy, # 270-a, Lees Summit, MO 64063 Phone: 816-524-1700 Fax: 816-524-1794 | |
Dr. Nicole Renee Graham, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 901 Ne Independence Ave, Lees Summit, MO 64086 Phone: 816-347-3223 | |
Dr. Michael E Williams, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 4045 Ne Lakewood Way Ste 130, Lees Summit, MO 64064 Phone: 816-886-2184 Fax: 816-886-2397 | |
Dr. John M Wubbenhorst Jr., DO Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 901 Ne Independence Ave, Lees Summit, MO 64086 Phone: 816-246-8000 Fax: 816-246-8207 |